C-RAD is a Swedish-based medtech company that provides solutions to ensure high precision, safety, and efficiency in advanced radiation therapy. More precisely, the company engages in the field of Surface Guided Radiation Therapy (SGRT), offering optical surface tracking for patient positioning and patient monitoring. SGRT offers the benefits of being non-ionising and non-invasive, while improving workflow and time efficiency. Headquartered in Uppsala, C-RAD has a global market presence (holding a ~30% global market share), and addresses a SEK 1.4bn annual opportunity.
We find the main risks to be market penetration risk, regulatory risks, increased competition, and innovation risks. SGRT is a relatively novel solution that still needs to be included in guidelines and to be further promoted by Key Opinion Leaders. Increased competition could potentially arise from linac OEMs deciding to put further efforts into developing their own SGRT solutions. Because the radiotherapy market is subject to high innovation, new technologies could potentially achieve the same kind of benefits as SGRT, and harm broader market adoption.